Center for Human Genetics and Laboratory Diagnostics, Dr. Klein, Dr. Rost and Colleagues

You are here: Pharmacogenetics » Adverse Drug Reactions due to Cytochrome P450 (Overview) » CYP1A2

Cytochrome P450 1A2 (CYP1A2) [T88.7]

OMIM number: 124060 (CYP1A2)

Dipl.-Biol. Birgit Busse

Scientific Background

CYP1A2 is involved in the oxidative metabolism of a range of drugs and pollutants. Interindividual differences in the metabolic capacity, however, can mainly be led back to enzyme inhibition or induction due to co-medication, diet or cigarette smoke. Furthermore, some variants in the CYP1A2 gene lead to an altered enzyme activity. Especially the CYP1A2*1F allele is associated with elevated inducibility of the enzyme as well as an accelerated metabolism. With a high frequency of approximately 70%, the allele is quite common in Caucasians. Furthermore, variants that result in reduced enzyme activity are also known.

Since the clinical relevance of the genetic variants is not completely clarified yet, the analysis is conducted only after prior consultation. For this enzyme inhibition or induction by various factors (e.g. diet, co-medication) has a much greater effect on enzyme activity than genetic disposition.